Nectar Life gets Japan’s nod for Cefuroxime; stock up

Nectar Lifesciences has received approval from the Japanese MOH for Cefuroxime Axetil. The company is expecting business potential of $ 10million from the molecule.

By ET Bureau | Mar 11, 2011, 03.22 PM IST

MUMBAI: Nectar Lifesciences has received approval from the Japanese MOH for Cefuroxime Axetil. The company is expecting business potential of $ 10million from the molecule.

The stock was at Rs 24.20, up 1.26 per cent on the BSE. It touched a high of Rs 25.20 and low of Rs 23.90 in trade so far.

Not making enough money in stocks? Click here for real-life stories of successful investors.

Too busy to trade in stocks? Invest in Mutual Funds with ET Money!